Compare ENR & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENR | MESO |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | ENR | MESO |
|---|---|---|
| Price | $20.21 | $19.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $27.00 | $24.00 |
| AVG Volume (30 Days) | ★ 1.3M | 230.2K |
| Earning Date | 02-03-2026 | 08-28-2025 |
| Dividend Yield | ★ 5.91% | N/A |
| EPS Growth | ★ 538.46 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $2,952,700,000.00 | $17,198,000.00 |
| Revenue This Year | $2.65 | $576.59 |
| Revenue Next Year | $1.09 | $41.15 |
| P/E Ratio | $6.12 | ★ N/A |
| Revenue Growth | 2.28 | ★ 191.39 |
| 52 Week Low | $16.77 | $9.61 |
| 52 Week High | $35.90 | $22.00 |
| Indicator | ENR | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 50.77 | 59.33 |
| Support Level | $19.55 | $19.00 |
| Resistance Level | $21.34 | $19.60 |
| Average True Range (ATR) | 0.81 | 0.55 |
| MACD | 0.24 | 0.04 |
| Stochastic Oscillator | 68.21 | 62.38 |
Energizer Holdings Inc makes and distributes household batteries, specialty batteries, and lighting products. Energizer offers batteries using lithium, alkaline, carbon-zinc, nickel-metal hydride, zinc-air, and silver oxide technologies. These products are sold under the Energizer, Rayovac, Varta and Eveready brands at performance and premium price segments. It also offers auto care products in the appearance, fragrance, performance, and air conditioning recharge product categories. The company operates in two geographical segments: Americas and International, of which the majority of its revenue is derived from the America. It has two product segments: Batteries & Lights and Auto Care. It earns maximum revenue from Batteries & Lights segment.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.